By Reuters
June 18, 2025 – 7:41 AM PDT
(Reuters) – Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk’s (NOVOb.CO) Wegovy and Eli Lilly’s (LLY.N) Zepbound result in both fat and muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients.
The following companies are developing weight-loss treatments that help preserve or grow muscles while patients shed pounds:
Advertisement
Eli Lilly
The U.S. drugmaker spent nearly $2 billion in 2023 to acquire Versanis Bio’s bimagrumab, which prevents the activity of a protein called myostatin to…



